← Back to contracts

HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)

US · US National Institutes of Health (NIH) grant open #PAR-25-154
Response due Jul 16, 2026 · 00:00 UTC

Summary

The NIH HEAL (Helping to End Addiction Long-term) Initiative is soliciting R03 small grant applications for early-stage discovery research aimed at identifying new pain targets within the understudied druggable proteome. This is a basic/translational science opportunity focused on uncovering novel molecular targets relevant to pain, explicitly excluding clinical trials. The opportunity is part of NIH's broader effort to accelerate the development of non-addictive pain treatments by exploring proteins not yet well-characterized in the context of pain biology.

What they want

Applicants must propose early-stage discovery research to identify and characterize new pain-relevant targets within the understudied druggable proteome. Clinical trials are not allowed under this funding mechanism. Research must align with the NIH HEAL Initiative's goals of advancing non-addictive pain therapeutics. The grant mechanism is R03 (NIH Small Research Grant Program), which typically supports small-scale, pilot, or feasibility studies with limited budgets and project periods.
Technical requirements
  • Research must focus on early-stage discovery of pain targets within the understudied druggable proteome
  • Clinical trials are explicitly not allowed
  • Must align with NIH HEAL Initiative objectives
  • R03 small grant mechanism applies (typically limited budget and 2-year project period)

How they evaluate

Submission: Electronic submission via Grants.gov and NIH ASSIST/eRA Commons per standard R03 application instructions referenced in PAR-25-154

Risks & flags

  • Long open window (12/11/2024 – 07/16/2026) with multiple submission cycles is standard for NIH PARs and not itself a red flag
  • No unusual sole-source indicators detected; standard NIH program announcement format

Market context

inferred from NAICS
R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)
NAICS 541715
US market size
$95B
Typical award
$100K – $50M+
Typical buyers
DoDNSFNIHNASADOE
Commonly required
DCAA-compliant accountingITARCMMC L2
HEAL Initiative-Early-Stage Discovery of N…
Due Jul 16
Onboard ↗